COVID-19 antibody / Berkeley Lights, Emory University, UC San Diego School of Medicine, Vanderbilt University Medical Center - LARVOL DELTA

Longitudinal Surveillance of COVID-19 Antibodies in Pediatric Healthcare Workers. (PubMed, Vaccines (Basel)) - "Anti-spike titers were more durable post-booster compared to the primary series. Longitudinal immune profiling of COVID-19 responses provides vital data to shape public health policies, optimize vaccine strategies, and strengthen pandemic preparedness."

Journal • Infectious Disease • Novel Coronavirus Disease • Pediatrics • Respiratory Diseases

Kinetics of the Antibody Response to Symptomatic SARS-CoV-2 Infection in Vaccinated and Unvaccinated Individuals in the Blinded Phase of the mRNA-1273 COVID-19 Vaccine Efficacy Trial. (PubMed, Open Forum Infect Dis) - "Following COVID-19, vaccinated participants had higher levels and greater breadth of antispike bAbs and higher nAb titers than unvaccinated participants. These were largely attributable to the primary immunization series."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Dengue Infection - Recent Advances in Disease Pathogenesis in the Era of COVID-19. (PubMed, Front Immunol) - "The consequences of a cross-reactivity between DENV and anti-SARS-CoV-2 responses are highly relevant in endemic areas. Here, we review the latest progress in the understanding of dengue immunopathogenesis and provide suggestions to the development of target strategies against dengue."

Journal • Review • Dengue Fever • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Application Of Tixagevimab And Cilgavimab In Patients With Adverse Events To Mrna Covid-19 Vaccines (ASM Microbe 2022) - "It is the only COVID-19 antibody that can be delivered intramuscularly. Among the AVAMC population who experienced adverse events to mRNA COVID-19 vaccination, there are 17 patients who are candidates for tixagevimab and cilgavimab. These findings will be shared with the Scarce Resources Committee and to increase awareness, develop an algorithm to risk-stratify, and further determine which patients qualify for tixagevimab and cilgavimab given its limited supply."

Adverse events • Clinical • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

[VIRTUAL] Donor-specific Anti-HLA Alloantibody in Kidney Transplant Recipients with COVID-19 Exhibit a Different Immunoglobulin Class and Subclass Profile When Compared to Anti-SARS-CoV-2 Antibodies (ATC 2021) - "Overall, these data suggests that kidney transplant recipients with Covid-19 exhibit a humoral immune response both to donor-HLA and SARS-CoV-2. Although both are protein antigens, the allo-immune response has a high-IgG/low IgA pattern, while the Covid-19 antibody profile includes high IgA. Additional follow-up is needed to determine if the increased IgA is a consistent marker of anti-SARS-CoV-2 antibody response."

Clinical • Late-breaking abstract • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • Transplantation